Ryan Preblick - 03 Mar 2026 Form 4 Insider Report for Indivior Pharmaceuticals, Inc. (INDV)

Reporting relationship: Chief Financial Officer
Issuer ticker: INDV
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 16:00:14 UTC
Prior SEC filing: 12 Feb 2026
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/Alice Givens, Power of Attorney

Key filing fact

Ryan Preblick filed Form 4 for Indivior Pharmaceuticals, Inc. (INDV) on 05 Mar 2026.

Key facts

This page summarizes Ryan Preblick's Form 4 filing for Indivior Pharmaceuticals, Inc. (INDV).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2026, 16:00.

Change

Previous filing in this sequence was filed on 12 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002014866 Primary reporting owner

Preblick Ryan

Relationship: Chief Financial Officer
Address: 10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD
Signature: /s/Alice Givens, Power of Attorney
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDV transaction

Common Stock

Tax liability

Transaction value
Shares: -87,597
Change %: -28%
Price: $31.98^*
Shares after: 230,343
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1

INDV transaction

Common Stock

Options Exercise

Transaction value
Shares: +86,949
Change %: +38%
Price
Shares after: 317,292
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDV transaction Derivative

Performance Stock Units

Options Exercise

Transaction value
Shares: -113,510
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 113,510
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

In 2024, 204,904 shares vested in respect of performance stock units granted to the Reporting Person on March 3, 2021. These shares were subject to a further two-year holding period. On March 3, 2026, the holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations.

Footnote F2

Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period.

Footnote F3

Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.